NCT01284634 - Study to Evaluate the Effect of GWP42003 on Liver Fat Levels in Participants With Fatty Liver Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 3, 2011

Primary Completion Date

July 13, 2012

Study Completion Date

July 13, 2012

Conditions

Fatty Liver

Interventions

DRUG

GWP42003 200 mg/day Dose

GWP42003 was presented as Licaps® size double zero (Size 00) hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).

DRUG

GWP42003 400 mg/day Dose

GWP42003 was presented as Licaps® Size 00 hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).

DRUG

GWP42003 800 mg/day Dose

GWP42003 was presented as Licaps® Size 00 hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).

DRUG

Placebo

Placebo was presented as Licaps® Size 00 hard gelatin capsules containing excipients (Gelucire 44/14).

Trial Locations (3)

London

Manchester

Manchester